| P50 | author | William E Grizzle | Q106555377 |
| P2093 | author name string | Donald J Buchsbaum | |
| | Lyudmila N Kaliberova | |
| | Sergey A Kaliberov | |
| | Cecil R Stockard | |
| P2860 | cites work | Identification and characterization of a new member of the TNF family that induces apoptosis | Q24318423 |
| | Cancer statistics, 2002 | Q28216788 |
| | An antagonist decoy receptor and a death domain-containing receptor for TRAIL | Q28245153 |
| | TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB | Q28259095 |
| | Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype | Q28345309 |
| | Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 |
| | Angiogenesis and prostate cancer tumor growth | Q30312026 |
| | Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy | Q30586812 |
| | Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector | Q31087174 |
| | Safety and antitumor activity of recombinant soluble Apo2 ligand | Q33855449 |
| | Apo2L/TRAIL and its death and decoy receptors | Q34532325 |
| | Gene therapy of prostate cancer: current and future directions | Q34744823 |
| | What's new in the treatment of advanced prostate cancer? | Q35037711 |
| | Angiogenesis and apoptosis | Q35091135 |
| | Radical radiotherapy for prostate cancer | Q35145698 |
| | Gene therapy progress and prospects: adenoviral vectors | Q35165719 |
| | Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy | Q35200626 |
| | Apoptosis-modulating agents in combination with radiotherapy-current status and outlook | Q35642871 |
| | Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels | Q36230478 |
| | CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy | Q38471453 |
| | Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo | Q40782543 |
| | Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis | Q40860890 |
| | Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer | Q40970843 |
| | Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. | Q40975748 |
| | Ionizing radiation greatly improves gene transfer efficiency in mammalian cells | Q41168436 |
| | Expression of vascular endothelial growth factor receptors in human prostate cancer | Q42477154 |
| | Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. | Q43931698 |
| | Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vect | Q44153756 |
| | Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer | Q44195530 |
| | Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells | Q44792608 |
| | Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft | Q45855281 |
| | Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer | Q45864105 |
| | Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors | Q45870079 |
| | Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium | Q45878726 |
| | Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice | Q46618427 |
| | CombiTool--a new computer program for analyzing combination experiments with biologically active agents. | Q52214209 |
| | De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. | Q52968592 |
| | Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. | Q53950070 |
| | Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer | Q60156367 |
| | Prostate cancer gene therapy | Q64378233 |
| | Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus | Q64379528 |
| | Tumor response to radiotherapy regulated by endothelial cell apoptosis | Q73401346 |
| | Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions | Q73704158 |
| P433 | issue | 6 | |
| P921 | main subject | Adenoviridae | Q193447 |
| | gene therapy | Q213901 |
| P304 | page(s) | 1059-1070 | |
| P577 | publication date | 2004-12-01 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer | |
| P478 | volume | 10 | |